BURLINGTON, MA, June 14, 2004— Cognos (NASDAQ: COGN; TSX; CSN) the world leader in enterprise business intelligence (EBI) and corporate performance management solutions, today announced a strategic OEM agreement with Phase Forward. Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, will integrate InFormT, its electronic data capture solution, with Cognos ReportNetT reporting technology. The new software version will be available later this year.

Phase Forward's InForm software is an Internet-enabled electronic data capture solution that reduces the inefficiencies, inaccuracies, and costs associated with paper-based clinical trials. With the InForm platform, pharmaceutical, biotechnology, and medical devices companies can conduct clinical trials with data managed electronically end-to-end, resulting in expedited trials, higher quality data, and lower costs.

Cognos ReportNet offers unrivaled enterprise reporting coverage, fully integrated within the Cognos Enterprise BI Series, including flexible powerful, industry-leading OLAP analysis, scorecards, dashboards, event detection and alerting, and data integration.

InForm's enhanced reporting capabilities will provide life sciences companies with real-time access to critical study data for better and faster clinical trial decision-making. InForm, through Cognos ReportNet technology integration, will enable operational and clinical data to be combined into actionable information based on user roles. Users will have drill-down capabilities to analyze and report at the patient, site, or trial level. InForm will leverage Cognos ReportNet's zero-footprint, web-based reporting architecture to provide a single reporting environment capable of supporting the spectrum of simple to complex reporting and query analysis.

Immediate and in-depth access to clinical and operational trial data will assist sponsor companies to streamline their clinical processes:

• Project managers can proactively monitor patient recruitment - sites lagging in enrollment or experiencing high patient dropout rates can be identified and assisted
• Trial managers can continuously review all aspects of clinical trial status in real-time, allowing for early detection of operational and safety concerns
• Monitors, through real-time reports on site and patient status, can more effectively plan and conduct their site visits. A monitor, for instance, can run site reports on patient visit schedules, outstanding queries, and investigator signature status to plan for an upcoming site visit.
• Data managers can run reports to spot and eliminate bottlenecks in data collection, query management, or data review. For example, a data manager may observe a high incident of queries from multiple clinical sites associated with a specific eCRF, indicating the need for the trial designers to review the eCRF for potential improvement.

"We chose to integrate Cognos ReportNet with our InForm solution because it is a market leading reporting solution, consistently top-rated by industry analysts," said Kathryn Roy, vice president, marketing, Phase Forward. "By delivering a state-of-the-art, comprehensive EDC reporting solution, we are enabling our customers to manage their clinical trials more efficiently and effectively."

"Phase Forward has the unparalleled industry expertise necessary to address the complex issues that face our joint customers in clinical trial management. The selection of Cognos as a strategic OEM partner is a clear indication of the significant competitive advantage our solution offers to the life sciences market," said Ted Jandl, vice president, strategic partners, Cognos. "Cognos looks forward to working with Phase Forward to deliver this combined solution to some of the most powerful pharmaceutical and biotechnology organizations in the world."

ABOUT PHASE FORWARD:
Phase Forward is a leading provider of integrated enterprise-level software products, services, and hosted solutions for use in the clinical trial component of its customers' global research and development initiatives. Phase Forward's customers include pharmaceutical, biotechnology, and medical device companies, as well as academic institutions, clinical research organizations, and other entities engaged in clinical trials. By automating essential elements of the clinical trial process, the company believes its products allow its customers to accelerate the market introduction of new medical therapies and corresponding revenue, reduce overall research and development expenditures, enhance existing data quality control efforts, and reduce clinical and economic risk. Phase Forward believes its enterprise software and hosted solutions are the most widely adopted commercial data capture, data management, and adverse event reporting solutions in the clinical trial marketplace, having been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants and 300 therapeutic compounds and medical devices. Phase Forward's customer base of over 220 customers is comprised of the leading pharmaceutical, biotechnology, medical device, and clinical research organizations, including AstraZeneca Pharmaceuticals LP, Corixa Corporation, Guidant Corporation, Eli Lilly and Company, Mayo Clinic College of Medicine, Novartis AG, and Schering-Plough Research Institute. Phase Forward is headquartered in Waltham, Massachusetts with offices in the United Kingdom, Australia, France, and Japan. Additional information about Phase Forward is available at www.phaseforward.com.